Letrozole Tablet, Film Coated
Product Images NDC 16729-034

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 16729-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Letrozole (Letrozole 100 Label)

Label for Letrozole Tablets USP 2.5 mg oral film-coated tablets by Accord Healthcare, Inc. The label indicates prescription use only and a package size of 100 tablets. Storage instructions specify controlled room temperature, and manufacturer details include Accord Healthcare, Inc. and Intas Pharmaceuticals Limited, India.*

FDA Label Image

Letrozole (Letrozole Carton)

Packaging label for Letrozole Tablets USP 2.5 mg by Accord Healthcare, Inc. The carton contains 100 tablets (10 x 10 unit-dose) of film-coated oral tablets. It features dosage strength, NDC 16729-034, manufacturing and storage information, and barcodes.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A line graph comparing treatment outcomes over time between Letrozole and Tamoxifen, showing the proportion of patients without an event over 72 months. The x-axis represents months from 0 to 72, and the y-axis represents the proportion from 0.0 to 1.0. The graph includes patient counts at risk at various time points and indicates treatment with solid line for Letrozole and dashed line for Tamoxifen.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A Kaplan-Meier curve chart comparing progression-free survival over time in months between Letrozole 2.5 mg tablets and Tamoxifen 20 mg. The vertical axis shows the proportion progression-free, and the horizontal axis represents months up to 60. Two lines depict the survival probabilities for each treatment group.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A survival curve chart comparing two groups: letrozole first and tamoxifen first, with the y-axis labeled "Alive" from 0.0 to 1.0 and the x-axis labeled "Months" from 0 to 60. The solid line represents letrozole first, and the dashed line represents tamoxifen first, showing the proportion alive over time.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A Kaplan-Meier survival curve chart showing time to progression in days for three treatment groups: Letrozole tablets 0.5 mg, Letrozole tablets 2.5 mg, and MA. The vertical axis represents the proportion without progression, and the horizontal axis shows time in days up to 1000.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A time-to-progression Kaplan-Meier survival curve chart displaying the progression over days for three treatment groups: Letrozole tablet 0.5 mg, Letrozole tablet 2.5 mg, and AG. The x-axis represents time to progression in days, and the y-axis shows the proportion of patients remaining progression-free.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure diagram of letrozole, showing its molecular framework with two cyanophenyl groups connected to a central triazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.